Suggestions
Julia Gaebler
Partner at Health Advances
Professional Background
Julia A. Gaebler, PhD, is a seasoned expert in health economics, policy, and market access strategies, currently serving as a Partner at Health Advances, LLC, a renowned Boston-based health care strategy consulting firm. With over two decades of professional experience in the health care sector, Dr. Gaebler leads the Global Market Access and Health Policy Practice at Health Advances, where she employs her extensive knowledge to navigate complex market dynamics and drive strategic initiatives for her clients. Her leadership is characterized by a deep understanding of payer landscapes, which has been essential in formulating successful global medical product strategies.
Before joining Health Advances, Dr. Gaebler held various prestigious positions in significant organizations within the health care industry. Most notably, she served as the Senior Director of Global Medical Outcomes Strategy at Biogen Idec, Inc., where she was responsible for integrating evolving global payer demands into medical product strategies. Her proactive approaches included spearheading payer value research that was pivotal for the launch and market acceptance of the multiple sclerosis treatments TECFIDERA and FAMPYRA, showcasing her ability to align innovative solutions with market needs.
Dr. Gaebler began her notable career at Amylin Pharmaceuticals in San Diego as the Director of Health Economics and Outcomes Research, where she supported strategic initiatives for the company's diabetes and obesity assets. Her role involved leveraging health economics to demonstrate the benefits of medical interventions, enhancing the understanding of product value among stakeholders and facilitating market access. Additionally, her earlier experience as a Health Policy Researcher at the RAND Corporation allowed her to apply decision-analytic methods to address pressing public health issues, fortifying her expertise in health policy formation.
Education and Achievements
Dr. Gaebler's impressive academic background underscores her authority in health policy and decision sciences. She earned her Doctor of Philosophy (PhD) in Health Policy and Decision Sciences from the prestigious Harvard University, a program renowned for its rigorous emphasis on analytical frameworks and policy implications in the health sector. Her academic prowess continued with a Master's degree in International Affairs and Economics from Johns Hopkins University, specifically from the esteemed Paul H. Nitze School of Advanced International Studies (SAIS). Furthermore, her undergraduate studies culminated in a Bachelor of Arts in History from the University of Pennsylvania, providing a strong foundation in critical thinking and contextual analysis.
Throughout her career, Dr. Gaebler has sought to bridge the gap between academic research and practical application within the health sector. This includes her work focused on modeling the effectiveness and cost-effectiveness of various medical interventions including treatment strategies for HIV, hepatitis B and C, and other infectious diseases. Moreover, her notable contributions to pharmacoeconomic analyses and Quality of Life assessments reflect her commitment to enhancing patient outcomes, illuminating her comprehensive understanding of the complexities involved in health care decision-making.
In addition to her main responsibilities, Dr. Gaebler has maintained academic affiliations, holding adjunct positions at the University of California, San Diego (UCSD) Division of Global Public Health and the RAND Corporation. These roles have allowed her to contribute to the academic community by mentoring the next generation of health policy professionals, fostering a culture of research and inquiry, and advancing the understanding of health economics principles among her students.
Achievements
Dr. Gaebler’s career is characterized by numerous achievements that exemplify her dedication and impact in health economics and policy. Her leadership in launching TECFIDERA and FAMPYRA at Biogen not only showcases her strategic vision but also highlights her ability to synchronize complex projects with stakeholder needs, setting the stage for successful market penetration and product acceptance.
At the RAND Corporation, Dr. Gaebler's research into public health prevention strategies examined pressing issues such as pandemic influenza and infectious disease policy, reinforcing her reputation as a thought leader in the field. Designing and executing models that effectively convey the value of health interventions has been fundamental to her approach, ensuring that critical data informs policy-making and health care delivery.
Her collaborations across different sectors of health care, from pharmaceuticals to public health, have allowed Dr. Gaebler to create impactful strategies that align scientific advancements with real-world applications, ultimately contributing to better health outcomes. Through her engagements in different capacities, she has garnered respect for her analytical expertise, her ability to foster relationships among stakeholders, and her insistence on the integration of evidence-based practices into health care decision-making.
Overall, Dr. Julia A. Gaebler stands as an influential figure in health economics and policy, combining her robust academic background, extensive industry experience, and commitment to excellence to influence the future of health care strategy. Her contributions to market access strategies and health policy are invaluable assets to the health care community.